Foscarnet, trisodium phosphonoformate, was administered intravenously to 6 immunosuppressed patients with life-threatening cytomegalovirus infection. Three of the patients were recipients of a kidney and 3 of a bone-marrow transplant. Favourable clinical responses were seen in 5 of the patients, 2 of whom were still in good health 5 and 8 months after the infection had cleared up. No toxic effect of the drug was detected. The results seem to justify further trials, in which foscarnet should be introduced at an earlier stage of the disease.
In a double-blind study 86 patients with a total of 129 episodes of recurrent genital herpes were treated topically with 0.3% foscarnet or placebo cream. All patients considered, healing time was significantly shortened in the foscarnet group as compared to the placebo group (p less than 0.01). Subgrouped by sex, the healing time among men treated with foscarnet was significantly shortened as compared to those treated with placebo (p less than 0.002), whereas no statistical significant difference was observed among women. Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1.7 days) than placebo (3.4 days) treated men (p less than 0.02). Overall, foscarnet treatment reduced the period of redness, swelling, blisters and ulcers. Foscarnet was well tolerated, only in 1/57 patients treated was a moderate local adverse reaction recorded.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.